Literature DB >> 22999988

Neurobehavioral assessment of infants born at term and in utero exposure to serotonin reuptake inhibitors.

Megan V Smith1, Anita Sung, Bhavesh Shah, Linda Mayes, Deborah S Klein, Kimberly A Yonkers.   

Abstract

BACKGROUND: Some studies report neurobehavioral symptoms in neonates exposed to serotonin reuptake inhibitors (SRIs) in utero. However, maternal psychiatric illness during the last trimester of pregnancy, as a confounding factor, has not always been assessed. AIMS: In this prospective study we compared neurobehavioral complications among neonates who were born to euthymic women who either took or did not take an SRI during the last trimester of pregnancy. STUDY
DESIGN: Exposed and unexposed infants were assessed for: 1) temperament as measured by the Neonatal Behavioral Assessment Scale (NBAS); 2) activity via Actiwatch electronic monitoring; 3) sleep state using trained observer ratings; and 4) perinatal complications through medical record review. T-tests, Fisher's exact tests, and analyses of covariance were used to assess the relationship between clinical and neurobehavioral factors and exposure status.
SUBJECTS: 67 infants (61 controls and 6 exposed to SRIs). OUTCOME MEASURES: Neonatal Assessment Behavioral Scale, APGAR scores, infant sleep state (% sleep, % wakeful), startles and tremulousness, gestational age, birth weight, and head circumference.
RESULTS: Infants exposed to SRIs in the third trimester had poorer motor development, lower 5-minute APGAR scores, and shorter mean gestational age as compared to unexposed infants.
CONCLUSION: Results of this study show differences in autonomic and gross motor activity between neonates who were or were not exposed to SRIs in utero after controlling for active maternal psychiatric illness. Future longitudinal work should compare longer term outcomes of exposed and unexposed infants of depressed mothers.
Copyright © 2012 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22999988      PMCID: PMC3921021          DOI: 10.1016/j.earlhumdev.2012.08.001

Source DB:  PubMed          Journal:  Early Hum Dev        ISSN: 0378-3782            Impact factor:   2.079


  24 in total

Review 1.  On categorizing gestational, birth, and neonatal complications following late pregnancy exposure to antidepressants: the prenatal antidepressant exposure syndrome.

Authors:  Salvatore Gentile
Journal:  CNS Spectr       Date:  2010-03       Impact factor: 3.790

2.  Fetal exposure to antidepressants and normal milestone development at 6 and 19 months of age.

Authors:  Lars Henning Pedersen; Tine Brink Henriksen; Jørn Olsen
Journal:  Pediatrics       Date:  2010-02-22       Impact factor: 7.124

3.  Effects of antenatal depression and antidepressant treatment on gestational age at birth and risk of preterm birth.

Authors:  Rita Suri; Lori Altshuler; Gerhard Hellemann; Vivien K Burt; Ana Aquino; Jim Mintz
Journal:  Am J Psychiatry       Date:  2007-08       Impact factor: 18.112

4.  Effects of selective serotonin reuptake inhibitors and venlafaxine during pregnancy in term and preterm neonates.

Authors:  Ema Ferreira; Ana Maria Carceller; Claire Agogué; Brigitte Zoé Martin; Martin St-André; Diane Francoeur; Anick Bérard
Journal:  Pediatrics       Date:  2007-01       Impact factor: 7.124

5.  Increasing use of antidepressants in pregnancy.

Authors:  William O Cooper; Mary E Willy; Stephen J Pont; Wayne A Ray
Journal:  Am J Obstet Gynecol       Date:  2007-06       Impact factor: 8.661

6.  A new look at the neonate's clinical presentation after in utero exposure to antidepressants in late pregnancy.

Authors:  Nina Boucher; Aida Bairam; Louise Beaulac-Baillargeon
Journal:  J Clin Psychopharmacol       Date:  2008-06       Impact factor: 3.153

7.  Developmental and behavioral consequences of prenatal fluoxetine.

Authors:  K L Bairy; S Madhyastha; K P Ashok; Indira Bairy; S Malini
Journal:  Pharmacology       Date:  2006-10-08       Impact factor: 2.547

8.  Major depression and antidepressant treatment: impact on pregnancy and neonatal outcomes.

Authors:  Katherine L Wisner; Dorothy K Y Sit; Barbara H Hanusa; Eydie L Moses-Kolko; Debra L Bogen; Diane F Hunker; James M Perel; Sonya Jones-Ivy; Lisa M Bodnar; Lynn T Singer
Journal:  Am J Psychiatry       Date:  2009-03-16       Impact factor: 18.112

9.  Sustained neurobehavioral effects of exposure to SSRI antidepressants during development: molecular to clinical evidence.

Authors:  T F Oberlander; J A Gingrich; M S Ansorge
Journal:  Clin Pharmacol Ther       Date:  2009-11-04       Impact factor: 6.875

10.  Infant serotonin transporter (SLC6A4) promoter genotype is associated with adverse neonatal outcomes after prenatal exposure to serotonin reuptake inhibitor medications.

Authors:  T F Oberlander; R J Bonaguro; S Misri; M Papsdorf; C J D Ross; E M Simpson
Journal:  Mol Psychiatry       Date:  2007-05-22       Impact factor: 15.992

View more
  11 in total

1.  Computer-assisted cognitive behavioral therapy for pregnant women with major depressive disorder.

Authors:  Deborah R Kim; Liisa Hantsoo; Michael E Thase; Mary Sammel; C Neill Epperson
Journal:  J Womens Health (Larchmt)       Date:  2014-09-30       Impact factor: 2.681

2.  The Roles of Maternal Depression, Serotonin Reuptake Inhibitor Treatment, and Concomitant Benzodiazepine Use on Infant Neurobehavioral Functioning Over the First Postnatal Month.

Authors:  Amy L Salisbury; Kevin E O'Grady; Cynthia L Battle; Katherine L Wisner; George M Anderson; Laura R Stroud; Cynthia L Miller-Loncar; Marion E Young; Barry M Lester
Journal:  Am J Psychiatry       Date:  2015-10-30       Impact factor: 18.112

Review 3.  Maternal use of antidepressant or anxiolytic medication during pregnancy and childhood neurodevelopmental outcomes: a systematic review.

Authors:  Hanan El Marroun; Tonya White; Frank C Verhulst; Henning Tiemeier
Journal:  Eur Child Adolesc Psychiatry       Date:  2014-05-27       Impact factor: 4.785

Review 4.  Antidepressant use in pregnant and postpartum women.

Authors:  Kimberly A Yonkers; Katherine A Blackwell; Janis Glover; Ariadna Forray
Journal:  Annu Rev Clin Psychol       Date:  2013-12-02       Impact factor: 18.561

5.  Antenatal depression, treatment with selective serotonin reuptake inhibitors, and neonatal brain structure: A propensity-matched cohort study.

Authors:  Shaili C Jha; Samantha Meltzer-Brody; Rachel J Steiner; Emil Cornea; Sandra Woolson; Mihye Ahn; Audrey R Verde; Robert M Hamer; Hongtu Zhu; Martin Styner; John H Gilmore; Rebecca C Knickmeyer
Journal:  Psychiatry Res Neuroimaging       Date:  2016-05-24       Impact factor: 2.376

6.  Fine Motor Differences and Prenatal Serotonin Reuptake Inhibitors Exposure.

Authors:  Marie-Claire A E Partridge; Amy L Salisbury; Linda L LaGasse
Journal:  J Pediatr       Date:  2016-05-20       Impact factor: 4.406

Review 7.  A review of environmental contributions to childhood motor skills.

Authors:  Jean Golding; Pauline Emmett; Yasmin Iles-Caven; Colin Steer; Raghu Lingam
Journal:  J Child Neurol       Date:  2013-10-29       Impact factor: 1.987

8.  Antidepressant Use During Pregnancy and the Potential Risks of Motor Outcomes and Intellectual Disabilities in Offspring: A Systematic Review.

Authors:  Nouf Al-Fadel; Adel Alrwisan
Journal:  Drugs Real World Outcomes       Date:  2021-02-12

9.  Effects of neonatal fluvoxamine administration on the physical development and activity of the serotoninergic system in white rats.

Authors:  N Yu Glazova; S A Merchieva; M A Volodina; E A Sebentsova; D M Manchenko; V S Kudrun; N G Levitskaya
Journal:  Acta Naturae       Date:  2014-07       Impact factor: 1.845

Review 10.  Neurodevelopmental outcome for offspring of women treated for antenatal depression: a systematic review.

Authors:  Giovanni Previti; Susan Pawlby; Sahmina Chowdhury; Eugenio Aguglia; Carmine M Pariante
Journal:  Arch Womens Ment Health       Date:  2014-09-12       Impact factor: 3.633

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.